Zobrazeno 1 - 8
of 8
pro vyhledávání: '"nivolumab and ipilimumab combined therapy"'
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 474-477 (2020)
Immune checkpoint inhibitors (ICIs) significantly prolong survival in patients with metastatic melanoma but can lead to serious immune-related adverse events. In this report, we described a case of atypical neuropathy caused by nivolumab plus ipilimu
Externí odkaz:
https://doaj.org/article/a38efd331a154b1392db1f612129eb7d
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 829-833 (2019)
Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports sugges
Externí odkaz:
https://doaj.org/article/6d680f621713413abe99f936a676f572
Autor:
Taku Fujimura, Yota Sato, Kayo Tanita, Chunbing Lyu, Yumi Kambayashi, Ryo Amagai, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Hiroo Hata, Takeru Funakoshi, Yumi Nonomura, Ryota Tanaka, Hisako Okuhira, Naoko Wada, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced
Externí odkaz:
https://doaj.org/article/60775cb304df4e02a56684d41b7ab84f
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 3, Pp 829-833 (2019)
Case Reports in Oncology
Case Reports in Oncology
Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports sugges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2971cde32881826d303b1885836e9626
https://www.karger.com/Article/FullText/504019
https://www.karger.com/Article/FullText/504019
Autor:
Hiroo Hata, Takeru Funakoshi, Yumi Kambayashi, Ryota Tanaka, Ryo Amagai, Atsushi Otsuka, Setsuya Aiba, Naoko Wada, Hisako Okuhira, Taku Fujimura, Yumi Nonomura, Yota Sato, Chunbing Lyu, Hiroshi Uchi, Yasuhiro Fujisawa, Yuki Yamamoto, Kayo Tanita, Koji Yoshino, Akira Hashimoto, Shigeto Matsushita
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Frontiers in Medicine
Frontiers in Medicine
Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05232b0d4dc7dad8db7773daca884b1b
https://www.frontiersin.org/article/10.3389/fmed.2019.00086/full
https://www.frontiersin.org/article/10.3389/fmed.2019.00086/full
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.